Author:
Zhang Shao-yan,Qiu Lei,Zhang Shun-xian,Xiao He-ping,Chu Nai-hui,Zhang Xia,Zhang Hui-qiang,Zheng Pei-yong,Zhang Hui-yong,Lu Zhen-hui
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Dadu A, Hovhannesyan A, Ahmedov S, van der Werf MJ, Dara M. Drug-resistant tuberculosis in eastern Europe and central Asia: a time-series analysis of routine surveillance data. Lancet Infect Dis 2020;20:250–258.
2. Singh V, Chibale K. Strategies to combat multi-drug resistance in tuberculosis. Acc Chem Res 2021;54:2361–2376.
3. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2020;8:383–394.
4. Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 2018;18:e183–e198.
5. Lu ZH, Zhang HY, Wu DZ, Guo XY, Geng PH, Yin GC, et al. The efficacy of combining the anti-tuberculosis regimen and Qingjin Granules in the treatment of chronic fibro-cavitary multidrug-resistant pulmonary tuberculosis patients with yin deficiency and lung heat syndrome. J New Chin Med (Chin) 2014;46:49–51.